Exp Clin Endocrinol Diabetes 2006; 114(7): 361-365
DOI: 10.1055/s-2006-924322
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Small Neuroendocrine Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1 (MEN1): Least Significant Change of Tumor Diameter as Determined by Endoscopic Ultrasound (EUS) Imaging

P. H. Kann1 , 4 , B. Kann1 , W. J. Fassbender3 , T. Forst4 , D. K. Bartsch2 , P. Langer2
  • 1Endocrinology & Diabetology, Philipp's University Medical School, Marburg, Germany
  • 2Surgery, Philipp's University Medical School, Marburg, Germany
  • 3Holy Ghost Academic Hospital, Kempen, Germany
  • 4Institute for Clinical Research and Development, Mainz, Germany
Weitere Informationen

Publikationsverlauf

Received: March 16, 2005 First decision: March 7, 2006

Accepted: April 24, 2006

Publikationsdatum:
16. August 2006 (online)

Abstract

Endosonography enables detection and localization of small pancreatic neuroendocrine tumors (PETs) which cannot be detected by computed tomography, magnetic resonance imaging, or somatostatin receptor scintigraphy. Knowledge about the prognosis of very small PETs in MEN1 is limited, and if there are no clinical symptoms, endocrine activity or mechanical problems and thus no clear indication for surgical therapy, an appropriate decision for the management of such patients might be to control their follow-up by endosonographic imaging. Therefore, the reproducibility of the measurement of the diameter of very small PETs by endosonographic imaging was investigated in this prospective study. We included 33 PETs smaller than 15 mm in their largest diameter detected by endosonographic imaging (Pentax FG 32 UA) in ten patients with genetically confirmed MEN1-disease. Three repeated measurements of each tumor were performed. Reproducibility was expressed as mean coefficient of variation of intra-observer variability. Mean tumor diameter was 6.9 ± 3.4 mm (range 2.8 - 14.2 mm). Mean coefficient of variation was 5.5 ± 4.6 % (range 0.0 - 19.4 %): in tumors < 5 mm (n = 13) 7.1 ± 6.3 %, in tumors > 5 mm (n = 20) 4.4 ± 2.6 %. Least significant change (p < 0.05) was calculated as 15.4 % (tumors < 5 mm: 19.9 %; tumors > 5 mm: 12.3 %). In conclusion, endosonographic imaging enables the measurement of small PETs with an acceptable reproducibility. Changes of tumor diameter of more than 20 % have to be taken as statistically significant.

References

  • 23 Bartsch D K, Langer P, Wild A, Schilling T, Celik I, Rothmund M, Nies C. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance?.  Surgery. 2000;  128 958-966
  • 28 Byrne M J, Nowak A K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.  Ann Oncol. 2004;  15 257-260
  • 18 Carty S E, Helm A K, Amico J A, Clarke M R, Foley T P, Watson C G, Mulvihill J J. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1.  Surgery. 1998;  124 1106-1113
  • 19 Chanson P, Cadiot G, Murat A. Management of patients and subjects at risk for multiple endocrine neoplasia type 1: MEN 1.  Horm Res. 1997;  47 211-220
  • 34 Cortes J, Rodriguez J, Diaz-Gonzalez J A, Garzon C, Gurpide A, Arbea L, Gil-Bazo I, Navarro V, Cambeiro M, Nicolas A I, Martin-Algarra S, Garcia-Foncillas J, Calvo E. Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer.  Br J Cancer. 2002;  87 158-160
  • 1 Dancygier H. Endoscopic ultrasonography in chronic pancreatitis.  Gastrointest Endosc Clin N Am. 1995;  5 1052-1057
  • 2 Devière J, Finet L, Dunham F, Cremer M. Endoscopic ultrasonography in chronic pancreatitis.  Endoscopy. 1994;  26 808-809
  • 21 Gauger P G, Scheiman J M, Wamsteker E J, Richards M L, Doherty G M, Thompson N W. Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1.  Br J Surg. 2003;  90 748-754
  • 3 Grimm H, Mayendo A, Soehendra N. Endoluminal ultrasound for the diagnosis and staging of pancreatic cancer.  Baillieres Clin Gastroenterol. 1990;  4 869-888
  • 31 James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P. Measuring response in solid tumors: unidimensional versus bidimensional measurement.  J Natl Cancer Inst. 1999;  91 523-528
  • 16 Kann P, Bittinger F, Engelbach M, Bohner S, Weis A, Beyer J. Endosonography of insulin-secreting and clinically non-functioning neuroendocrine tumors of the pancreas: criteria for benignancy and malignancy.  Eur J Med Res. 2001;  6 385-390
  • 17 Kann P H, Wirkus B, Keth A, Goitom K. Pitfalls in endosonographic imaging of suspected insulinomas: pancreatic nodules of unknown dignity.  Eur J Endocrinol. 2003;  148 531-534
  • 14 Kann P H, Wirkus B, Behr T, Klose K ‐J, Meyer S. Endosonographic imaging of benign and malignant pheochromocytomas.  J Clin Endocrinol Metab. 2004;  89 1694-1697
  • 15 Kann P H. Endosonographic imaging of the adrenals.  Endoscopy. 2005;  37 244-253
  • 22 Langer P, Kann P H, Fendrich V, Richter G, Diehl S, Rothmund M, Bartsch D K. Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors (PETs) in patients with multiple endocrine neoplasia type 1 (MEN1).  World J Surg. 2004;  28 1317-1322
  • 4 Lees W R. Endoscopic ultrasonography of chronic pancreatitis and pancreatic pseudocysts.  Scand J Gastroenterol Suppl. 1986;  123 123-129
  • 29 Mazumdar M, Smith A, Schwartz L H. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.  J Clin Epidemiol. 2004;  57 358-365
  • 25 McHugh K, Kao S. Response evaluation criteria in solid tumours (RECIST): problems and need for modifications in paediatric oncology?.  Br J Radiol. 2003;  76 433-436
  • 30 Miller A B, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment.  Cancer. 1981;  47 207-214
  • 5 Müller M F, Meyerberger C, Bertschinger P, Schaer R, Marincek B. Pancreatic tumors: Evaluation with endoscopic US, CT, and MR imaging.  Radiology. 1994;  190 745-751
  • 6 Nattermann C, Dancygier H. Endosonographie bei Tumoren des Pankreas und der Gallenwege.  Leber Magen Darm. 1993;  1 13-23
  • 7 Nattermann C, Goldschmidt A JW, Dancygier H. Endosonography in chronic pancreatitis - a comparison between endoscopic retrograde pancreatography and endoscopic ultrasonography.  Endoscopy. 1993;  25 565-570
  • 8 Nattermann C, Goldschmidt A JW, Dancygier H. Endosonographie in der Dignitätsbeurteilung von Pankreastumoren.  Dtsch Med Wochenschr. 1995;  120 1571-1576
  • 20 Owen N J, Sohaib S A, Peppercorn P D, Monson J P, Grossman A B, Besser G M, Reznek R H. MRI of pancreatic neuroendocrine tumours.  Br J Radiol. 2001;  74 968-973
  • 24 Padhani A R, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists.  Br J Radiol. 2001;  74 983-986
  • 26 Park J O, Lee S I, Song S Y, Kim K, Kim W S, Jung C W, Park Y S, Im Y H, Kang W K, Lee M H, Lee K S, Park K. Measuring response in solid tumors: comparison of RECIST and WHO response criteria.  Jpn J Clin Oncol. 2003;  33 533-537
  • 9 Rösch T, Lorenz R, Braig C, Feuerbach S, Siewert J R, Classen M. Endosonographische Diagnostik bei Pankreastumoren.  Dtsch Med Wochenschr. 1990;  115 1339-1347
  • 33 Therasse P, Arbuck S G, Eisenhauer E A, Wanders J, Kaplan R S, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom A T, Christian M C, Gwyther S G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.  J Natl Cancer Inst. 2000;  92 205-216
  • 35 Trillet-Lenoir V, Freyer G, Kaemmerlen P, Fond A, Pellet O, Lombard-Bohas C, Gaudin J L, Lledo G, Mackiewicz R, Gouttebel M C, Moindrot H, Boyer J D, Chassignol L, Stremsdoerfer N, Desseigne F, Moreau J M, Hedelius F, Moraillon A, Chapuis F, Bleuse J P, Barbier Y, Heilmann M O, Valette P J. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria.  Br J Radiol. 2002;  75 903-908
  • 32 van Klaveren R J, Aerts J G, de Bruin H, Giaccone G, Manegold C, van Meerbeeck J P. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.  Lung Cancer. 2004;  43 63-69
  • 27 Watanabe H, Yamamoto S, Kunitoh H, Sekine I, Yamamoto N, Ohe Y, Tamura T, Kodama T, Sugimura K, Saijo N. Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients.  Cancer Sci. 2003;  94 1015-1020
  • 10 Wiersema M J, Hawes H, Lehmann G A, Kochmann M L, Sherman S, Kopecky K K. Prospective evaluation of endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in patients with chronic abdominal pain of suspected pancreatic origin.  Endoscopy. 1993;  25 555-564
  • 11 Wiersema M J, Wiersema L M. Endosonography of the pancreas: normal variation versus changes of early chronic pancreatitis.  Gastrointest Endosc Clin N Am. 1995;  5 487-496
  • 12 Yasuda K, Mukai H, Fujimoto S, Nakajiama M, Kawai K. The diagnosis of pancreatic cancer by endoscopic ultrasonography.  Gastrointest Endosc. 1988;  134 1-8
  • 13 Zuccaro Jr G, Sivak Jr M V. Endoscopic ultrasonography in the diagnosis of chronic pancreatitis.  Endoscopy. 1992;  24 347-349

M.D., Professor of Endocrinology Peter Herbert Kann

Head Division of Endocrinology & Diabetology
Philipp's University Hospital

35033 Marburg

Germany

Telefon: + 4964212863135

Fax: + 49 642 12 86 27 33

eMail: Kannp@med.uni-marburg.de

    >